

## **eLOS ONLINE COURSE**

## Management of antibody-drug conjugate (ADC) related ocular adverse events

## 30 September 2025

WEBINAR

Time: 18:00 - 20:00 CEST

ESASO Scientific Director: Mario Romano Course Scientific Coordinator: Martina Angi

Moderator: Martina Angi

Welcome and Introduction	Moderator: Martina Angi (Italy)	18:00-18:05 5 Min.
ADCs: what are they and what do they do to the eye?  Overview of ADCs used in oncology and their ocular adverse events	Philipp Steven (Germany)	18:05-18:25 20 Min.
Multidisciplinary approach in the management of ADC- related ocular adverse events		18:25-18:45
Patients education and preventing strategies, referral pathways in case of symptoms, use of common terminology	Sajjad Ahmad (UK)	20 Min.
to grade toxicity, shared decision-making on treatment adjustment		
Mirvetuximab Soravtansine (MIRV): a first-in-class ADC	_	
for platinum-resistant ovarian cancer	Domenica Lorusso (Italy)	18:45-19:05
Brief introduction on ovarian cancer, speaking about the unmet need in platinum resistant ovarian cancer and presenting the most important efficacy and safety data with MIRV		20 Min.
MIRV-related ocular adverse events and how to manage	_	
them	Jutta Winter-Horwath (Austria)	19:05-19:25
Data on ocular safety profile of MIRV, emphasizing the		20 Min.
differences to other ADCs, providing indications on the		
correct management of its ophthalmic side effects	_	





## **eLOS ONLINE COURSE**

Real-life experience with MIRV: case 1  Patient case presentation and further considerations	Maximilian Groeben (Germany)	19:25-19:35
		10 Min.
Real-life experience with MIRV: case 2 Patient case presentation and further considerations	Gerald Schmidinger (Austria)	19:35-19:45
		10 Min.
Real-life experience with MIRV: case 3 Patient case presentation and further considerations	Maximilian Groeben (Germany)	19:45-19:55
		10 Min.
Discussion / Q & A	Moderator + All speakers	19:55-20:05 10 Min.
Take home message and closing remarks	Moderator: Martina Angi (Italy)	20:05-20:10 5 Min.

An application will be made to EACCME® for CME accreditation of this event.